NCT03926741View on ClinicalTrials.gov

GSNOR Phenotyping/GSNO Challenge in Severe Asthma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
AsthmaHealthy Volunteers
Interventions
DRUG

GSNO

patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Cleveland

46202

Indiana University School of Medicine, Indianapolis

All Listed Sponsors
collaborator

University Hospitals Cleveland Medical Center

OTHER

collaborator

Case Western Reserve University

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

James Reynolds

OTHER

NCT03926741 - GSNOR Phenotyping/GSNO Challenge in Severe Asthma | Biotech Hunter | Biotech Hunter